StoxEmcure Pharmaceuticals vs Sai Life Sciences: share price & financials comparison
NSE: EMCURE vs SAILIFE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Sai Life Sciences at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹41,979 Cr, against ₹37,919 Cr for Sai Life Sciences (SAILIFE). Over the past year Sai Life Sciences has returned +94.7%, compared with +65.2% for Emcure Pharmaceuticals. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 38.4 versus 187.2. Emcure Pharmaceuticals earns a higher return on equity (20.5% vs 7.5%). Emcure Pharmaceuticals comes out ahead on size, valuation, profitability and growth. Sai Life Sciences comes out ahead on financial health, momentum and technicals. Across the scored metrics below, Emcure Pharmaceuticals leads on 7 and Sai Life Sciences on 5. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Sai Life Sciences scores 6/10.
| Metric | Emcure Pharmaceuticals | Sai Life Sciences |
|---|---|---|
| Size | ||
| Market cap | ₹41,979 Cr | ₹37,919 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹2,192 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹349 Cr |
| Valuation | ||
| P/E | 38.4 | 187.2 |
| P/B | 7.86 | 14.11 |
| Dividend yield | 0.14% | — |
| Profitability | ||
| Return on equity | 20.5% | 7.5% |
| Net profit margin | 10.7% | 8.5% |
| Operating margin | 20.4% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +22.5% |
| Net profit growth (YoY) | +33.7% | — |
| Financial health | ||
| Debt to equity | 0.27 | 0.17 |
| Momentum | ||
| 1-month return | +15.4% | +14.3% |
| 1-year return | +65.2% | +94.7% |
| Distance from 52W high | -1.4% | +0.0% |
| Technicals | ||
| RSI (14) | 81 | 93 |
| Price vs 200-day avg | +27.3% | +47.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Sai Life Sciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Sai Life Sciences?
Emcure Pharmaceuticals has a market cap of ₹41,979 Cr and Sai Life Sciences has a market cap of ₹37,919 Cr as of 06 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Sai Life Sciences?
Emcure Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 38.4 and Sai Life Sciences at 187.2.
Which gave better returns in the last year, Emcure Pharmaceuticals or Sai Life Sciences?
Sai Life Sciences did better: Emcure Pharmaceuticals returned +65.2% and Sai Life Sciences returned +94.7% over one year.
Is Emcure Pharmaceuticals or Sai Life Sciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Emcure Pharmaceuticals scores 9/10 and Sai Life Sciences scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.